Immediate Impact
62 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
Works of Ze Cong being referenced
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
2019
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ze Cong | 159 | 113 | 63 | 210 | 43 | 433 | |
| Benjamin Barnes | 85 | 117 | 31 | 245 | 29 | 506 | |
| Roman M. Shapiro | 186 | 75 | 48 | 148 | 44 | 475 | |
| Binay Kumar Shah | 145 | 61 | 101 | 126 | 45 | 456 | |
| Andrew Hantel | 115 | 109 | 55 | 114 | 58 | 460 | |
| Rejiv Rajendranath | 138 | 116 | 105 | 122 | 29 | 428 | |
| E De Cock | 72 | 33 | 46 | 157 | 48 | 495 | |
| Hasmukh Jain | 71 | 121 | 54 | 187 | 79 | 391 | |
| Noortje Thielen | 204 | 81 | 155 | 139 | 22 | 485 | |
| Gabriel Tremblay | 117 | 44 | 39 | 104 | 83 | 396 | |
| Thuan V. Tran | 91 | 54 | 90 | 156 | 22 | 448 |
All Works
Loading papers...